GSK1349572

Bezeichnung:GSK1349572

CAS-Nr1051375-16-6

Englisch Name:GSK1349572

CBNumberCB62538916

SummenformelC20H19F2N3O5

Molgewicht419.38

MOL-Datei1051375-16-6.mol

GSK1349572 physikalisch-chemischer Eigenschaften

Schmelzpunkt	187-189°C
Siedepunkt	669.0±55.0 °C(Predicted)
Dichte	1.53
storage temp.	Refrigerator
Löslichkeit	DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated, Sonicated)
pka	4.50±1.00(Predicted)
Aggregatzustand	Solid
Farbe	White to Pale Beige

Sicherheit

Giftige Stoffe Daten

1051375-16-6(Hazardous Substances Data)

Gefahreninformationscode (GHS)

GSK1349572 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
In August 2013, the US FDA approved dolutegravir (also referred to as S/GSK1349572) for the treatment of HIV-1 infection in adults and children ages 12 years and older in combination with other antiretroviral drugs. Dolutegravir was approved in Canada in November 2013. HIV/AIDS remains a global epidemic with 35 million people infected, including 2.3 million new infections as of 2012. Dolutegravir joins raltegravir and elvitegravir (this chapter of ARMC) as the latest of three FDA-approved HIV integrase strand transfer inhibitors (INSTIs). Dolutegravir was discovered by rational design from a literature diketo acid HIV integrase inhibitor utilizing X-ray coordinates to predict ideal bond angles between the diketone and distal benzyl group. In dolutegravir, the monocyclic component of the reported inhibitor was replaced with the tricyclic carbamoyl pyridone moiety. The researchers postulated that the appropriate arrangement of three oxygens would permit chelation with two magnesium ions in the binding site thus affording improved potency. Ultimately, this arrangement along with further modifications afforded dolutegravir, a potent inhibitor of HIV integrase (IC₅₀=1.7 nM).
Chemische Eigenschaften
White Solid
Originator
Shionogi & GlaxoSmithKline (United States)
Verwenden
Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
Definition
ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]ox zine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1.
Trademarks
Tivicay
Clinical Use
Integrase inhibitor:
Treatment of HIV
target
HIV integrase
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Antidepressants: concentration reduced by St John’s wort.
Antiepileptics: concentration reduced by carbamazepine and possibly fosphenytoin, oxcarbazepine, phenobarbital, phenytoin and primidone.
Antivirals: concentration reduced by efavirenz, tipranavir, etravirine and fosamprenavir; possibly reduced by nevirapine.
Stoffwechsel
Dolutegravir is primarily metabolised through glucuronidation via UGT1A1 with a minor CYP3A component.
53% of the total oral dose is excreted unchanged in the faeces. It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen.

GSK1349572 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

1051375-16-6, GSK1349572 Verwandte Suche:

Send Inquriy